New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
17:20 EDTMGNXMacroGenics IND MGD007 cleared by FDA to start enrolling patients
MacroGenics announced that its investigational new drug, or IND, for MGD007 has been cleared by the FDA to proceed with the phase 1 human clinical trial for this drug candidate. MGD007 is a Dual-Affinity Re-Targeting protein being developed for the treatment of colorectal cancer. MacroGenics will receive a $5M milestone payment from Servier, France's largest privately-held pharmaceutical company, triggered by the IND clearance.
News For MGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
07:20 EDTMGNXEuro Organization for Research & Treatment of Cancer co-hosts a symposium
Subscribe for More Information
November 12, 2014
11:17 EDTMGNXLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
07:21 EDTMGNXMacroGenics strategic change positive, says Stifel
Subscribe for More Information
November 11, 2014
16:09 EDTMGNXMacroGenics to start study in breast cancer instead of gastroesophageal cancer
Subscribe for More Information
16:06 EDTMGNXMacroGenics reports Q3 EPS (14c), consensus (42c)
Subscribe for More Information
15:43 EDTMGNXLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use